Samsung Bioepis has submitted a biosimilar version of Roche's breast cancer blockbuster Herceptin in the EU, hard on the heels of rivals Biocon and Mylan.
Merck’s Keytruda could become a national tourist attraction in China, with a special approval for imports to the resort island of Hainan.
Learn why pharma companies must invest in digital technologies and how those that do can grow market share and revenue.
With forced price cuts for brands such as Gilead Sciences' hep C med Sovaldi already under its belt, the Japanese government is weighing others to help…
Hepatitis C is a big problem in China, and drugmakers are still waiting on approval for their next-gen treatments. Now, regulators are promising action--and…
Pharma companies are risking the wrath of India's drugs regulator by ignoring a demand for clinical trials of combination drugs.
Government warns drugmakers could leave the UK if the country's separation from the EU drags on and is kept under wraps.
Mitsubishi Tanabe is hoping to end a 20-year drought in the U.S. for new ALS medicines.
Biocon and partner Mylan have moved one step closer to launching a Herceptin biosimilar in Europe--and they claim they've beaten their rivals to the punch…
Bristol-Myers Squibb partner Ono Pharmaceutical bagged a third approval in Japan for immuno-oncology drug Opdivo, its most important new product.
The Japan leg of a major postmarketing study on Bayer's Xarelto set a milestone in patient numbers.